ADCE-D01

N/A

Report date: 2025/10/21 14:45:50
First In Class

Base Information

Drug NameADCE-D01
Drug Alias NameADCE-D01
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Antibody drug conjugate (ADC)
Mechanisms of ActionC-type mannose receptor 2 modulatorsTubulin polymerisation inhibitors
TargetsC-type mannose receptor 2Tubulin
Therapy Area/IndicationsSarcomaMesenchymoma
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryBelgiumUnited StatesDenmark +[6] 
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaN/A
Originator CompaniesAdcendo APS
China Registration ClassN/A

Develop Information

Active CompaniesAdcendo APS
Inactive CompaniesN/A
Active IndicationsSarcomaMesenchymoma
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A